Role of Cytokines and Other Soluble Factors in Tumor Development: Rationale for New Therapeutic Strategies

Cavazzoni, Andrea; Digiacomo, Graziana

doi:10.3390/cells12212532

Cells

2023

DOI: 10.3390/cells12212532

|View full text |Cite

Role of Cytokines and Other Soluble Factors in Tumor Development: Rationale for New Therapeutic Strategies

Andrea Cavazzoni,

Graziana Digiacomo

Abstract: Many cytokines control tumor development by directly lowering cancer cell proliferation and inducing apoptotic cell death, or indirectly by activating the antitumoral activity of specific immune cells such as NK or CD8+ T-lymphocytes [...]

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Expression of Interleukin-8, Interleukin-12 and Interleukin-13 in Esophageal Squamous Cell Carcinoma: Biomarker Potentiality and Prognostic Significance

Talukdar,

Malik,

Kataki

et al. 2024

J Gastrointest Canc

View full text Add to dashboard Cite

Expression of Interleukin-8, Interleukin-12 and Interleukin-13 in Esophageal Squamous Cell Carcinoma: Biomarker Potentiality and Prognostic Significance

Talukdar,

Malik,

Kataki

et al. 2024

J Gastrointest Canc

View full text Add to dashboard Cite

Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy

Xu,

Wang,

2024

Cytokine & Growth Factor Reviews

View full text Add to dashboard Cite

Present and Future of Immunotherapy for Triple-Negative Breast Cancer

Sriramulu,

Thoidingjam,

Speers

et al. 2024

Cancers

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) lacks the expression of estrogen receptors (ERs), human epidermal growth factor receptor 2 (HER2), and progesterone receptors (PRs). TNBC has the poorest prognosis among breast cancer subtypes and is more likely to respond to immunotherapy due to its higher expression of PD-L1 and a greater percentage of tumor-infiltrating lymphocytes. Immunotherapy has revolutionized TNBC treatment, especially with the FDA’s approval of pembrolizumab (Keytruda) combined with chemotherapy for advanced cases, opening new avenues for treating this deadly disease. Although immunotherapy can significantly improve patient outcomes in a subset of patients, achieving the desired response rate for all remains an unmet clinical goal. Strategies that enhance responses to immune checkpoint blockade, including combining immunotherapy with chemotherapy, molecularly targeted therapy, or radiotherapy, may improve response rates and clinical outcomes. In this review, we provide a short background on TNBC and immunotherapy and explore the different types of immunotherapy strategies that are currently being evaluated in TNBC. Additionally, we review why combination strategies may be beneficial, provide an overview of the combination strategies, and discuss the novel immunotherapeutic opportunities that may be approved in the near future for TNBC.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Role of Cytokines and Other Soluble Factors in Tumor Development: Rationale for New Therapeutic Strategies

Abstract: Many cytokines control tumor development by directly lowering cancer cell proliferation and inducing apoptotic cell death, or indirectly by activating the antitumoral activity of specific immune cells such as NK or CD8+ T-lymphocytes [...]

Cited by 3 publications

References 10 publications

Expression of Interleukin-8, Interleukin-12 and Interleukin-13 in Esophageal Squamous Cell Carcinoma: Biomarker Potentiality and Prognostic Significance

Expression of Interleukin-8, Interleukin-12 and Interleukin-13 in Esophageal Squamous Cell Carcinoma: Biomarker Potentiality and Prognostic Significance

Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy

Present and Future of Immunotherapy for Triple-Negative Breast Cancer

Contact Info

Product

Resources

About